NCT00726323 - A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

August 18, 2010

Study Completion Date

August 18, 2010

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

foretinib (formerly GSK1363089 or XL880)

treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule

Trial Locations (12)

19104

GSK Investigational Site, Philadelphia

20892

GSK Investigational Site, Bethesda

37232

GSK Investigational Site, Nashville

44195

GSK Investigational Site, Cleveland

46202

GSK Investigational Site, Indianapolis

48201

GSK Investigational Site, Detroit

78229

GSK Investigational Site, San Antonio

94115

GSK Investigational Site, San Francisco

94305

GSK Investigational Site, Stanford

94904-2007

GSK Investigational Site, Greenbrae

02115

GSK Investigational Site, Boston

08901

GSK Investigational Site, New Brunswick